Actym Therapeutics
Jonathan Zhu has a diverse work experience in various roles and industries. Jonathan is currently working as a Process Development Engineer at Actym Therapeutics, Inc. starting in May 2022. Prior to that, they worked as a Research Associate II, Cancer Organoid at resistanceBio from July 2021 to May 2022. From October 2020 to July 2021, Jonathan was a Research Associate, Engineered Cells at Synthego Corporation.
Before their roles in the biotech industry, Jonathan gained experience in the healthcare sector. Jonathan worked as a Clinical Coordinator at O&A Healthcare Solutions from May 2019 to November 2019. In this role, they were involved in managing scheduling, revenue optimization, and treatment reports for multiple clinics. Jonathan also handled patient appointments and ensured patient satisfaction.
Jonathan's earlier experience includes an Undergraduate Research Internship at the University of Chicago from June 2018 to October 2018. During this time, they published a paper on gastric cancer treatment trials and performed gene editing experiments. Jonathan also worked as a Gastrointestinal Research Intern at Rush University Medical Center from June 2017 to September 2017, where they conducted protein identification and Western blot experiments related to leaky gut syndrome.
Additionally, Jonathan has experience working as a Mathematics Tutor at Barrington High School from August 2013 to May 2016. Overall, their work experience showcases their ability to excel in research, engineering, and coordination roles in both academic and industry settings.
Jonathan Zhu attended Barrington High School from 2012 to 2016 where they obtained their High School Diploma. Following that, they pursued a Bachelor's degree at UCLA from 2016 to 2020 with a focus on Biology/Biological Sciences, General.
This person is not in the org chart
This person is not in any teams
Actym Therapeutics
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies,STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.